FDA Approval

This content is for subscribers only. Please click here to see our plans.

This content is for subscribers only. Please click here to see our plans.

This content is for subscribers only. Please click here to see our plans.

This content is for subscribers only. Please click here to see our plans.

This content is for subscribers only. Please click here to see our plans.

biotech & health insights 🧬 Biotech News: BeyondSpring, Lexaria, Outlook, Omeros, INOVIO & Abeona Move on Key Developments Biotech stocks saw significant volatility as companies announced regulatory progress, strategic partnerships, financing transactions, commercial updates and quarterly results. Here are the key developments investors were watching. 🎯 BeyondSpring Gains on Orphan Drug Designation BeyondSpring (NASDAQ: BYSI) shares surged 34% to close…

This content is for subscribers only. Please click here to see our plans.

This content is for subscribers only. Please click here to see our plans.

This content is for subscribers only. Please click here to see our plans.

This content is for subscribers only. Please click here to see our plans.

This content is for subscribers only. Please click here to see our plans.

This content is for subscribers only. Please click here to see our plans.

This content is for subscribers only. Please click here to see our plans.

This content is for subscribers only. Please click here to see our plans.

biotech & health insights 🧬 Biotech Weekly Preview: High-Impact Phase 3 Catalysts to Watch 📅 The Week Ahead in Biotech Biotech earnings season is underway, but quarterly results are only part of the story. For clinical-stage companies, Phase 3 clinical catalysts can create much larger stock-moving events, particularly when pivotal data could determine the future of an asset, trigger a…